Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Segments and Strategy
JNJ logo

Johnson & Johnson's $85.2 Billion Sales Surge Driven by Innovative Medicine and MedTech, Despite $6.9 Billion Talc Litigation Charge

JNJ10-KFiling Date: 2/16/2024
Johnson & Johnson
Description

What this story covers

Johnson & Johnson's 2023 sales hit 85 point 2 billion dollars, up 6 point 5 percent, driven by Innovative Medicine (STELARA, DARZALEX) and MedTech (Abiomed acquisition). Despite strong R&D (15 point 1 billion dollars) and cash flow, a 6 point 9 billion dollar talc litigation charge impacted earnings, highlighting significant legal challenges.

Story snapshot

CompanyJohnson & Johnson
TickerJNJ
VariantStandard detailed
Duration31:56
Filing type10-K
PeriodAnnual 2023
IndustryHealthcare & Pharmaceuticals
Accession0000200406-24-000013

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in